GDF11: The Disputed Blood Protein That Reversed Heart Ageing in Mice

Facebook ↗WhatsApp ↗

Originally published 2017-07-03.

GDF11 and Ageing Research in Mice

In May 2013, two researchers at the Harvard Stem Cell Institute reported that a protein found in the blood, GDF11, could reverse one sign of heart ageing in mice. When old mice were given the protein, their thickened heart walls shrank back towards the size seen in young animals. The work, published in the journal Cell, made headlines as a possible "youth protein".

The short answer to whether scientists found an age-reversing protein is: they found a promising signal in mice, and then the science became much messier. In 2015 a team at Novartis challenged the central finding that GDF11 declines with age, and the question is still not settled. No GDF11 treatment has been approved for people. This article explains what the original study showed, why it excited cardiologists, what the critics found, and where research stands now.

What the Harvard team found

The study was led by Richard T. Lee, a cardiologist at Brigham and Women’s Hospital and professor at Harvard Medical School, and Amy Wagers, a professor in Harvard’s Department of Stem Cell and Regenerative Biology. Postdoctoral researcher Francesco Loffredo, the paper's first author, carried out much of the analysis of the mouse hearts.

As mice age, like people, the walls of their hearts tend to thicken and the heart muscle cells grow larger, a change called cardiac hypertrophy. The team found that this change could be reversed in old mice, first by connecting them to the bloodstream of young mice and then by injecting a single protein. After treatment, the old hearts were smaller, with thinner walls and smaller muscle cells, resembling those of younger animals.

GDF11 and Ageing Research in Mice

The researchers also checked whether a fall in blood pressure might explain the effect. They built a device to measure blood pressure in the mice's tails and concluded that it did not, which pointed to a factor carried in the blood itself.

How the experiment worked: shared blood between young and old

The key technique was heterochronic parabiosis, a surgical method that joins two animals of different ages so that they share a circulation. Wagers had already used it to study how young blood affects ageing muscle and stem cells.

In the heart study, old mice were paired with young partners for four weeks. Their enlarged hearts regressed markedly. Because the effect could not be explained by changes in blood pressure or behaviour, the team searched for a blood-borne substance responsible. Using a protein-screening technique based on modified aptamers (molecules that bind specific proteins), they identified GDF11, a member of the TGF-beta family of signalling proteins, as a factor that appeared to be abundant in young mice and scarcer in old ones.

GDF11 and Ageing Research in Mice

They then injected old mice with GDF11 to bring levels up to what they measured in youth. The treatment reproduced the effect of sharing blood with a young partner, reducing heart wall thickness within about a month.

Why cardiologists were excited

The findings touched on a real gap in medicine. A large share of older patients with heart failure have what is now called heart failure with preserved ejection fraction, often known as diastolic heart failure. Their hearts pump with normal force but are stiff and thickened, so they do not fill properly. The condition is strongly linked to age, high blood pressure, obesity and diabetes, and for many years there were few treatments shown to help.

Lee described patients who repeatedly came into hospital to have excess fluid removed, went home, and returned again, because doctors lacked drugs that changed the course of the disease. He called the project "the coolest thing I've ever been a part of," and Harvard Stem Cell Institute co-director Doug Melton described the discovery as huge.

Lee estimated at the time that clinical trials might begin within four or five years. The work was funded in part by the Harvard Stem Cell Institute, the US National Institutes of Health and the American Heart Association.

GDF11 and Ageing Research in Mice

The 2015 challenge from Novartis

In 2014 the Wagers group and colleagues published further papers linking GDF11 to the repair of ageing muscle and to new blood vessel and nerve cell growth in the brain. GDF11 briefly became the leading explanation for why young blood seemed to rejuvenate old animals.

Then, in May 2015, a team led by David Glass at the Novartis Institutes for Biomedical Research reported in Cell Metabolism that the tests used to measure GDF11 could not tell it apart from myostatin, a closely related protein about 90% similar in structure that is well known for limiting muscle growth. Using a more specific test, the Novartis group found that GDF11 levels in rats and humans actually rise with age. In injured mouse muscle, high doses of GDF11 impaired repair rather than helping it.

Wagers stood by her results. She suggested that there may be more than one form of GDF11, perhaps only one of which declines with age, and pointed out that the Novartis experiments used more severe injuries and higher doses, so the results were not directly comparable. Both sides' data hinted at a common point: too much or too little of the protein could be harmful.

Other independent scientists said the Novartis methods were thorough, while noting that the brain and blood vessel findings had yet to be tested in the same way. Later work by several groups showed that high levels of GDF11 can cause muscle wasting in mice, which added to the doubts about using it as a general anti-ageing drug.

Where GDF11 research stands now

The idea did not disappear. In 2018 Wagers and Lee were among the founders of Elevian, a start-up set up to develop GDF11-based medicines for heart disease, stroke, Alzheimer's disease, type 2 diabetes and age-related muscle loss. It initially raised $5.5 million and later more, and it said it planned to start human studies. As of the latest public reports, no GDF11 therapy has been approved, and the outcome of any human trials has not been published.

Basic research has continued to find roles for GDF11 in the body. It helps control skeletal patterning in the developing embryo and influences the nervous system, blood vessels and kidneys. A 2023 study in Nature Aging reported that GDF11 given to old mice improved memory and reduced depression-like behaviour, apparently by boosting a cellular clean-up process called autophagy in neurons. Lower GDF11 levels have also been reported in people with major depression. These are leads, not treatments.

Myths and practical takeaways

  • Myth: scientists have found a protein that reverses ageing. The 2013 study reversed one feature of heart ageing in mice. It did not make the animals younger overall, and the measurement behind it was later disputed.
  • Myth: young blood can rejuvenate people. Parabiosis studies in mice are not evidence that transfusions of young plasma help humans. There is no approved anti-ageing blood treatment, and commercial "young blood" infusions carry real risks.
  • Myth: GDF11 is either good or bad. Like many signalling proteins, its effects seem to depend on dose, tissue and context.
  • Takeaway: mouse results are a starting point. Many treatments that work in mice fail in human trials, and every new drug must be tested for safety and benefit before use.

For people living with heart failure, the most reliable advice is unchanged: follow the treatment plan agreed with your care team, and talk to a doctor before trying any supplement or experimental product sold as anti-ageing.

The video below gives an overview of the original research and the excitement it generated at the time.

Sources: Harvard Gazette, 9 May 2013: Making old hearts younger; Scientific American, 19 May 2015: “Young blood” anti-aging mechanism called into question; Fierce Biotech, 7 September 2018: Elevian set up to pursue disputed approach to aging diseases; Wikipedia: GDF11. Photo credit as given in the original post: thirdexodus.org.

COMMENTS